Covalon Technologies Ltd. (OTCMKTS:CVALF) Sees Large Decline in Short Interest

Covalon Technologies Ltd. (OTCMKTS:CVALF - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 100 shares, a decline of 92.3% from the December 15th total of 1,300 shares. Based on an average trading volume of 20,700 shares, the days-to-cover ratio is currently 0.0 days.

Covalon Technologies Stock Performance

Shares of OTCMKTS:CVALF traded down $0.09 during midday trading on Monday, reaching $2.12. The company had a trading volume of 7,466 shares, compared to its average volume of 35,381. The company has a fifty day simple moving average of $2.49 and a two-hundred day simple moving average of $2.20. The firm has a market cap of $58.02 million, a price-to-earnings ratio of -70.56 and a beta of -0.27. Covalon Technologies has a 1-year low of $0.74 and a 1-year high of $3.08.

Covalon Technologies (OTCMKTS:CVALF - Get Free Report) last posted its quarterly earnings data on Tuesday, January 7th. The company reported $0.01 EPS for the quarter. Covalon Technologies had a negative net margin of 2.94% and a negative return on equity of 4.40%.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.